COVID_19 variant KP.2 has spread in many countries and is highly contagious
period Trash Bags Factory Many adjustments have also been made, and the direction of product research and development has been reversed, in order to better meet the market demand. https://jixingpack.com/product-category/bags/trash-bags/
From May 7 to 13, a COVID-19 variant named KP2 was spreading all over the world. In early May this year, the World Health Organization (WHO) listed the KP2 subvariety as a surveillance variant.
MVK, head of COVID-19 technology in World Health Organization (WHO), said that KP2 is a descendant pedigree of JN1, while JN1 is the main strain in the world, and KP2 spike protein has an extra mutation. There are other emerging variants, JN1 continues to evolve, and we will continue to closely monitor the evolution of the virus.
According to the latest “epidemic situation of novel coronavirus infection in China in April 2023” released by the Chinese Centers for Disease Control and Prevention, no two mutants have been found in China. The report shows that from April 1 to April 30, 2024, 31 provinces (autonomous regions, municipalities directly under the Central Government) and Xinjiang production and Construction Corps reported a total of 11299 local cases of novel coronavirus genome effective sequences, all of which were Omicron mutants. The main epidemic strains were JN1 series variants, and the top three were JN1, JN14 and JN116.
On May 13, Zhao Wei, director of the Biosafety Research Center of the School of Public Health of Southern Medical University, told People’s Daily Health client reporter that considering that the infected people already had certain antibody levels and immune barriers, even if there were new mutants, the symptoms of the current variants are still mainly mild and asymptomatic infections. In addition, the emergence of new mutants indicates that novel coronavirus has not disappeared, and the virus is still mutating. from a clinical point of view, although the current mutants have increased the advantage of transmission, there is no difference between the clinical symptoms of the infected person and the previous strains. At present, there is no significant increase in pathogenicity, and the serious disease rate should not increase.
According to the picture, “the epidemic situation of novel coronavirus infection in China in April 2023”.
The KP2 mutant is a derivative of JN1. There is a point mutation of two amino acids on the outermost spike protein, resulting in increased infectivity, which may be the main reason why it has quickly become the mainstream mutant. Internationally, it has surpassed JN1 to become the main epidemic strain in some countries. Therefore, many people are worried about triggering a new round of infection peak, but it needs to be clear that as long as the pathogenicity does not increase significantly. You don’t have to worry too much for the time being. Zhao Wei explained.
According to the reporter, globally, the KP2 mutant has begun to spread in many countries around the world. According to the data released by the Centers for Disease Control and Prevention (CDC) on May 10, a COVID-19 mutant named KP2 has replaced JN1 as the main epidemic strain in the United States. On May 9, local time, GN reported that KP2 quickly dominated Canada. As of April 28, national data showed that KP2 accounted for 266% of all COVID-19 cases in Canada, more than other JN1 subvariants.
From the clinical observation, this mutant is still as contagious as other O mutants, but its pathogenicity is weak. At this stage, the emergence of new variants of the virus will not have a significant impact on everyone’s normal life, but there may still be severe cases for the elderly and people with low immunity, so remind these high-risk people to continue to pay attention to the information released by the relevant departments and do a good job of personal protection during the epidemic. Zhao Wei warned that it is still possible for the virus to mutate in the future to produce strains with more transmission advantages, and even do not rule out the emergence of strains with strong virulence, and it is necessary to continuously monitor virus changes and develop safer and effective vaccines. (People’s Daily Health client reporter Wang Aibing)